Sponsored content brought to you by In the rapidly advancing field of immuno-oncology research, there has been increasing ...

Sunshine Biopharma Inc. has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA lipid nanoparticle (K1.1-mRNA-LNP) product as a novel therapeutic agent for ...

In the mouse model and human tumor samples, MAGE-4 drives the accumulation of plasma immune cells that suppress antitumor immunity. The study points at novel potential therapeutic avenues that ...

They conducted experiments using two mouse models: a preventive model targeting C ... jejuni vaccine significantly reduced tumor incidence and accelerated the clearance of C.

deepening understanding of MOA and potential patient response Combination of a mouse analog of MICVO and a mouse anti-PD-1 therapy in a syngeneic model resulted in significantly greater tumor ...

Hoth Therapeutics (HOTH) announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for ...

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...